Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P43146 (tumour suppressor)
 5,935 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tumour development is a disease of both somatic and genetic origin. It originates from a combination of oncogene and tumour suppressor alterations that force the cell into unprogrammed proliferation. It is reasonable to think that a genetic disease could be cured by gene therapy, and several strategies along this line are presently being employed. The use of retroviruses to carry 'suicide' genes has been the most successful approach to date for the treatment of neurological malignancies. The use of adenoviruses with deletions in the E1B region opens a new and elegant possibility for the destruction of tumours deficient in the p53 suppressor gene. Strategies based on the inhibition of angiogenesis are being developed, and those based on blockade of inducers of angiogenesis have given encouraging results in experimental animal models. However, gene therapy has not yet been able to permanently cure a human genetic disease, thereby creating a certain degree of caution among scientists and clinicians.
 ...
PMID:An overview of gene therapy approaches to neurological malignancies. 1802 May 69

Novel treatment strategies such as gene therapy are warranted in view of the failure of current treatment approaches to cure a high percentage of patients with advanced bladder cancers. The emergence of cancer gene therapy potentially offers a number of exciting treatments. The majority of approaches involve strategies to suppress the function of activated oncogenes to restore the expression of functional tumour suppressor genes or to initiate tumour self-destruction. One gene therapy approach against tumours that holds great promise is suicide gene therapy. Herpes simplex virus thymidine kinase (HSV-TK) phosphorylates ganciclovir (GCV), which in turn interacts with cellular DNA polymerase and interferes with DNA synthesis to cause death of rapidly dividing cells. The development of an effective delivery system is absolutely critical to the usefulness and safety of gene therapy. At present, the adeno-associated virus (AAV) vector has the most promising potential in view of its non-pathogenicity, wide tropisms and long-term transgene expression in vivo. Gene therapy studies using different serotypes of recombinant AAV (rAAV) as delivery vehicles have proved rAAVs to be an effective modality of cancer gene therapy. In the present study, we investigated the suppression effect of AAV-mediated HSV-TK/GCV system on the bladder cancer cells and in mice xenograft models of bladder cancer. Our data demonstrate that rAAV-HSV-TK system controlled tumour cell growth and achieves strong antitumour efficacy in vivo. These findings provide a foundation for the development of potential targeted clinical therapies for bladder cancer in humans.
 ...
PMID:The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma. 2201 35


<< Previous 1 2 3